Foundayo tablets for weight loss
Foundayo (orforglipron) is a prescription-only, once-daily tablet for weight management in adults, used alongside a reduced-calorie diet and more activity. Unlike other GLP-1 tablets, it can be taken at any time of day, with or without food.2
Check your eligibility →- CQC registered
- UK-registered clinicians
- Plain, discreet delivery
All content on this page has been medically reviewed by Naeem Teni, Clinical Lead. GPhC 2215591.
What is Foundayo?
Foundayo (orforglipron) is a prescription-only, once-daily tablet for weight management in adults, used alongside a reduced-calorie diet and more activity. Unlike other GLP-1 tablets, it can be taken at any time of day, with or without food.2
A clinician reviews your assessment before anything is prescribed, and is there if you have questions along the way.
How does Foundayo work?
- A different kind of GLP-1. Orforglipron acts on the same GLP-1 receptor as semaglutide, but it's a small-molecule medicine rather than a peptide. That's why it doesn't need an empty stomach to be absorbed.1
- Hunger turns down. For many people that means less hunger between meals and feeling full sooner, so eating less takes less effort.
- Digestion slows. It slows how quickly your stomach empties, so food stays with you longer.
- Your changes do the rest. It supports changes to how you eat and move rather than replacing them, which is what helps results hold.
How much does Foundayo cost?
We're finalising prices for Foundayo. Your clinician confirms the cost before anything is prescribed.
How do I use Foundayo?
- Pick a time. Any time of day works. Choose one you'll remember.2
- Food or no food. There's no need to fast or wait before eating.2
- Follow your plan. Your dose steps up over time. Don't change it without talking to your clinician.
- Keep it in the pack. Store tablets in their original packaging, as the leaflet explains.
Missed a dose? Check your leaflet or ask your clinician. Don't take two doses to make up for one.
How does Foundayo compare with other options?
Figures are average weight loss at the highest dose in each medicine's main trial, alongside diet and activity. They come from different trials in different people, so they aren't a direct ranking. The one direct comparison: when tirzepatide (Mounjaro) and injected semaglutide (Wegovy) were tested head to head over 72 weeks, average weight loss was 20.2% and 13.7%.6
| Foundayo | Mounjaro | Wegovy | Wegovy Pill | |
|---|---|---|---|---|
| Type | Orforglipron · Daily tablet | Tirzepatide · Weekly injection | Semaglutide · Weekly injection | Semaglutide · Daily tablet |
| Average weight loss in main trial | 11.2% over 72 weeks1 | 20.9% over 72 weeks3 | 14.9% over 68 weeks4 | 13.6% over 64 weeks5 |
| Key points | Acts on GLP-1 Any time of day, with or without food | Acts on GIP and GLP-1 Same day each week | Acts on GLP-1 Same day each week | Acts on GLP-1 On an empty stomach with a sip of water, 30 minutes before food |
| Price | See pricing | £149 a month | £119 a month | £99 a month |
| This page | View Mounjaro → | View Wegovy → | View Wegovy Pill → |
Is Foundayo right for me?
It isn't suitable for everyone. Your assessment covers all of this, and a clinician checks your answers before anything is prescribed.
Usually suitable if
- You're an adult, 18 or over, living in the UK.
- Your BMI is 30 or more, or 27 or more with a weight-related condition such as high blood pressure or type 2 diabetes.
- You're ready to use it alongside changes to how you eat and move.
- A clinician judges it safe with your health history and medicines.
Not suitable if
- You're pregnant, planning a pregnancy, or breastfeeding.
- You have a history of medullary thyroid cancer or MEN 2.
- You're allergic to orforglipron or any of its ingredients.
- You have certain conditions, such as severe gastrointestinal disease.
Quick check
What's my BMI?
BMI is only a guide. A clinician looks at your whole health history.
What are the side effects of Foundayo?
Stomach-related side effects were the most common in trials. They tend to happen early on or after a dose increase, and ease with time.1
More common
Usually mild and short-lived
Rare
Get help straight away if
- Severe stomach pain that won't go away, sometimes reaching your back.
- Pain in the upper right of your stomach, fever, or yellowing skin or eyes.
- Vomiting or diarrhoea that stops you keeping fluids down.
- Swelling of your face, lips or throat, or trouble breathing.
Pregnant or planning to be? Foundayo isn't for use in pregnancy. Tell your clinician if you're planning a family.
Foundayo FAQs
Is Manova a proper clinic, or a website?
Will it turn up in a branded box at my office?
What if the clinician says no?
Am I locked into a contract?
How is this different from going to my GP?
Read up on Foundayo
References (6)
- Wharton S, et al. Orforglipron, an oral small-molecule GLP-1 receptor agonist for obesity treatment (ATTAIN-1). N Engl J Med. 2025;393(18):1796–1806.
- Foundayo (orforglipron) prescribing information and FDA approval announcement. Eli Lilly and Company, 2026.
- Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med. 2022;387:205–216.
- Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 2021;384:989–1002.
- Wharton S, et al. Oral semaglutide at a dose of 25 mg in adults with overweight or obesity (OASIS 4). N Engl J Med. 2025;393(11):1077–1087.
- Aronne LJ, et al. Tirzepatide as compared with semaglutide for the treatment of obesity (SURMOUNT-5). N Engl J Med. 2025.